Hypertension Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
For people with preeclampsia:
- People diagnosed with preeclampsia before 34 weeks of pregnancy, within the last 48 hours, and with no birth planned within the next week
- People receiving pregnancy care at the John Radcliffe Hospital
- People aged 19 to 45 years
- People who are willing and able to give their consent to take part in the study
For people with normal blood pressure (comparison group):
- People aged 19 to 45 years who are willing and able to give their consent to take part
- People who have had normal blood pressure (below 140/90) throughout their pregnancy
- People with fewer than 2 moderate risk factors for high blood pressure during pregnancy, as defined by UK national health guidelines
- People whose blood test results show a specific protein ratio (sFlt/PlGF) below 35 (confirm with trial site)
Who may not be able to join:
For people with preeclampsia:
- People with a history of serious heart problems, including uncontrolled irregular heartbeat, unstable chest pain, severe heart failure, or heart valve disease
- People with a history of long-term kidney disease
- People who cannot take folic acid or folate-related supplements for any reason
- People taking more than 400 micrograms of folate supplements in the third trimester of pregnancy
- People with low vitamin B12 levels in their blood
- People currently taking proton pump inhibitors (a type of medication for stomach acid) or anti-epileptic medications
- People experiencing organ complications (confirm with trial site)
- People whose baby has been diagnosed with a chromosomal condition involving an extra chromosome (such as Down syndrome, trisomy 18, or trisomy 13)
- People whose baby has a known heart defect or is considered at high risk of heart disease
- People whose baby has a known infection
- People whose baby has been diagnosed with severe anaemia
For people with normal blood pressure:
- People who have been diagnosed with any high blood pressure condition during pregnancy
- People taking beta-blocker medications such as atenolol or similar drugs
- People with a history of serious heart problems, including uncontrolled irregular heartbeat, unstable chest pain, severe heart failure, or heart valve disease
- People with a history of long-term kidney disease
- People whose baby has been diagnosed with a chromosomal condition involving an extra chromosome
- People whose baby has a known heart defect or is considered at high risk of heart disease
- People whose baby has a known infection
- People whose baby has been diagnosed with severe anaemia
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Paul Leeson, FRCP, University of Oxford, John Radcliffe Hospital
Phone: 01865 572833
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To assess the change of maternal circulating BH4 biomarkers levels at baseline to prior to delivery.; To assess the change of maternal nitric oxide levels at baseline to prior to delivery.; To assess the levels of BH4 biomarkers in umbilical cord blood.; To assess the levels of BH4 biomarkers in placenta.; To assess the levels of nitric oxide levels in umbilical cord blood.; To assess the levels of nitric oxide levels in placenta.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.